Dr. David Fajgenbaum, MD, MBA, MSc, discusses his diagnosis of idiopathic multicentric Castleman disease. He discusses his successes with drug repurposing for Castleman disease and shares his unique and valuable insights in bringing together physicians, researchers and patients from around the world to work together to find treatments.

The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) is an FDA-funded initiative with the goal of accelerating therapy development across rare diseases. The platform serves as a centralized and standardized infrastructure to host and share rare diseases data, to support and accelerate rare disease innovation. RDCA-DAP is well positioned to generate solutions to drug development bottlenecks. As such, the utility of patient-level data is maximized and data may be used to develop tools that will be accessible to the community in order to optimize and accelerate drug development across rare diseases.

Subscribe to C-Path Now ►► [ Ссылка ]

FOLLOW C-PATH: LinkedIn: [ Ссылка ]
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]

ABOUT C-PATH: Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path US is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.

#CPath #nonprofit #globalhealth #Castlemandisease #collaboration #consortium #biomarkers #NORD #RDCADAP #raredisease #datasharing

свернуть